3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Thoracic
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Sarcoma
1
Dermatologic
1
Conditions
Sarcoma
4
Gliosarcoma
4
Glioblastoma
4
Brain Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Melanoma
2
Liposarcoma
2
Endometrial Neoplasms
2
Carcinosarcoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Platinum-Refractory Fallopian Tube Carcinoma
1
Pharyngeal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasms
1
Interventions
pembrolizumab
7
Cyclophosphamide
6
Nivolumab
4
fludarabine
3
spartalizumab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
zanidatamab
1
vocimagene amiretrorepvec
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tinostamustine
1
talazoparib
1
sarilumab
1
sargramostim
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Immunoglobulin G
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled